ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.839,03
-1,15%
S&P 500
5.712,20
-1,12%
Dow Jones
42.454,79
-0,31%
Euro vs US Dollar
1,07545
0,12%
Bitcoin
87.391,88
0,58%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Roivant Sciences Ltd (ROIV)

  7. Roivant Sciences Ltd (ROIV) News

ROIV

Roivant Sciences (ROIV)

Roivant Sciences Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ROIV
DatumZeitQuelleÜberschriftSymbolFirma
19/03/202512h45GlobeNewswire Inc.Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesNASDAQ:ROIVRoivant Sciences Ltd
18/03/202521h32GlobeNewswire Inc.Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsNASDAQ:ROIVRoivant Sciences Ltd
03/03/202515h15GlobeNewswire Inc.Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaNASDAQ:ROIVRoivant Sciences Ltd
03/03/202515h15GlobeNewswire Inc.Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaNASDAQ:ROIVRoivant Sciences Ltd
25/02/202514h00GlobeNewswire Inc.Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus BoardNASDAQ:ROIVRoivant Sciences Ltd
10/02/202513h00GlobeNewswire Inc.Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
03/02/202513h00GlobeNewswire Inc.Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch CareNASDAQ:ROIVRoivant Sciences Ltd
29/01/202522h05GlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025NASDAQ:ROIVRoivant Sciences Ltd
28/01/202503h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
28/01/202503h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
03/12/202413h00GlobeNewswire Inc.Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisNASDAQ:ROIVRoivant Sciences Ltd
03/12/202413h00GlobeNewswire Inc.Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary SarcoidosisNASDAQ:ROIVRoivant Sciences Ltd
12/11/202413h00GlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
29/10/202421h35GlobeNewswire Inc.Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024NASDAQ:ROIVRoivant Sciences Ltd
28/10/202414h25GlobeNewswire Inc.Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NASDAQ:ROIVRoivant Sciences Ltd
18/09/202413h30GlobeNewswire Inc.Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NASDAQ:ROIVRoivant Sciences Ltd
10/09/202412h30GlobeNewswire Inc.Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) ActivatorNASDAQ:ROIVRoivant Sciences Ltd
10/09/202412h30GlobeNewswire Inc.Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society CongressNASDAQ:ROIVRoivant Sciences Ltd
09/09/202413h00GlobeNewswire Inc.Roivant Provides Update on Graves’ Disease Development ProgramNASDAQ:ROIVRoivant Sciences Ltd
08/08/202413h00GlobeNewswire Inc.Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
25/07/202422h05GlobeNewswire Inc.Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024NASDAQ:ROIVRoivant Sciences Ltd
31/05/202403h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
30/05/202422h46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ROIVRoivant Sciences Ltd
30/05/202413h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202413h00GlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
23/05/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
16/05/202422h05GlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024NASDAQ:ROIVRoivant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:ROIV

Kürzlich von Ihnen besucht

NYSE
KEG
Key Energy Services
TSX
2464
Aoba BBT
TSX
NVEI
Nuvei
NYSE
LPI
Laredo Petroleum
NYSE
LTH
Life Time
NYSE
OUT
OUTFRONT Media
BIT
3UBS
Leverage Certificate on ...
NEO
CHEV
Chevron CDR
TSX
GIGC
Guardian Investment Grad...
EU
LCJP
Lyxor Asset Management L...
BIT
BELL
Bellini Nauttica
NEO
LABZ
Metaspere Labs
LSE
FA52
Astrazeneca 27
TSX
247A
AI Robotics
TSX
IUTE
Invesco S&P US Total Mar...
CSE
QBOT
Quantum Cobalt
Delayed Upgrade Clock
ADVFN Logo
Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten